Merck & Co., Inc. $MRK Position Increased by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd raised its position in Merck & Co., Inc. (NYSE:MRK) by 18.2% during the first quarter, HoldingsChannel.com reports. The firm owned 270,465 shares of the company’s stock after buying an additional 41,648 shares during the quarter. Merck & Co., Inc. makes up approximately 0.9% of Dai ichi Life Insurance Company Ltd’s holdings, making the stock its 18th largest holding. Dai ichi Life Insurance Company Ltd’s holdings in Merck & Co., Inc. were worth $32,534,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Analysts Set New Price Targets

Several analysts have commented on MRK shares. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Guggenheim raised their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 13th. BMO Capital Markets lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Trading Up 0.4%

Shares of NYSE:MRK opened at $131.06 on Friday. The company has a market cap of $323.68 billion, a P/E ratio of 36.92, a P/E/G ratio of 5.18 and a beta of 0.19. The stock’s 50-day moving average is $121.67 and its 200-day moving average is $117.71. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the firm earned $2.22 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were issued a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.